Physician profile
Rafaz Hoque
NPI 1801086673
$1,423.44
in general payments reported to CMS, 2019-2025
17 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2024: $593 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $211.67 | 2024-2025 | |
| Janssen Biotech, INC. | $197.86 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $187.40 | 2024-2025 | |
| Pfizer INC. | $136.41 | 2024-2025 | |
| Covidien LP | $106.49 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.52 | 2024-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $92.75 | 2025 | Sucraid |
| Ardelyx, INC. | $61.99 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $60.49 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $55.50 | 2024-2025 | Entyvio, Eohilia |
| Merck Sharp & Dohme LLC | $52.77 | 2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $47.71 | 2024 | |
| Sandoz INC. | $28.81 | 2024 | Hyrimoz |
| Celltrion USA INC. | $24.40 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $21.81 | 2025 | Suflave, Sutab |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $20.93 | 2024 | Iqirvo |
| Madrigal Pharmaceuticals | $16.93 | 2024 | Resmetirom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafaz Hoque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.